Tortoise Investment Management’s Keros Therapeutics KROS Stock Holding History

Tortoise Investment Management’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-312	Closed	-$9.95K	–	807
2023 Q3	$9.95K	Hold	312	–	–	﹤0.01%	558
2023 Q2	$12.5K	Hold	312	–	–	﹤0.01%	525
2023 Q1	$13.3K	Hold	312	–	–	﹤0.01%	512
2022 Q4	$15K	Hold	312	–	–	﹤0.01%	496
2022 Q3	$12K	Hold	312	–	–	﹤0.01%	502
2022 Q2	$9K	Hold	312	–	–	﹤0.01%	530
2022 Q1	$17K	Hold	312	–	–	﹤0.01%	444
2021 Q4	$18K	Hold	312	–	–	﹤0.01%	418
2021 Q3	$12K	Hold	312	–	–	﹤0.01%	448
2021 Q2	$13K	Buy	312 +219	+235%	+$11.9K	﹤0.01%	433
2021 Q1	$6K	Buy	+93	New	+$5.89K	﹤0.01%	483

Other funds holding KROS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Tortoise Investment Management's KROS Position: Q4 2023 in Review

Tortoise Investment Management sold out of Keros Therapeutics (KROS) in Q4 2023, closing a stake of 312 shares — an estimated $9.95K sold.

Tortoise Investment Management first reported a position in KROS in Q1 2021 and held it in 11 quarters. The position peaked at $18K in Q4 2021. 121 funds tracked by Wall St. Rank hold KROS as of Q4 2023.

Tortoise Investment Management reported no remaining Keros Therapeutics position as of Q4 2023 after selling out during the quarter.
Tortoise Investment Management sold 312 Keros Therapeutics shares in Q4 2023, an estimated $9.95K.
Tortoise Investment Management first reported a position in Keros Therapeutics in Q1 2021 and held it in 11 quarters.
Tortoise Investment Management's Keros Therapeutics position peaked at $18K in Q4 2021.
121 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2023.

Based on Tortoise Investment Management's 13F filing for Q4 2023, filed 8 Feb 2024.